Table of Contents

• What Are Somatotropic Research Peptides?
• Which Compounds Are Available in the True Peptide Labs Somatotropic Category?
• What Is the Somatotropic Axis?
• What Are the Categories of Somatotropic Research Peptides?
• Which Somatotropic Research Peptides Are Most Studied?
• What Is the Importance of Somatotropic Research Peptides in Preclinical Science?
• What Is the Difference Between GHRPs and GHRH Analogs?
• What Research Protocols Are Described in the Somatotropic Peptide Literature?
• Are Somatotropic Research Peptides Studied in Combination?
• What Dose Ranges Appear in Published Somatotropic Peptide Studies?
• What Endpoints Are Measured in Somatotropic Peptide Research?
• How Is Receptor Selectivity Characterized in Somatotropic Peptide Research?
• What Signaling Pathways Do Somatotropic Research Peptides Engage?
• What Model Systems Are Used in Somatotropic Peptide Research?
• What Adverse Events Have Been Reported in the Somatotropic Peptide Research Literature?
• In What Form Do Somatotropic Research Peptides Ship?
• How Are Somatotropic Research Peptides Tested for Purity?
• How to Purchase Somatotropic Research Peptides Online
• What Is the Difference Between Somatotropic and Myogenic Research Peptides?

What Are Somatotropic Research Peptides?

Somatotropic research peptides are synthetic peptide and small-molecule compounds used in laboratory studies to investigate the growth hormone secretagogue system, the growth hormone-releasing hormone system, and downstream IGF-1 signaling in rodent GH-sampling protocols, pituitary somatotroph primary cultures, and receptor-transfected in vitro systems. These compounds act at the growth hormone secretagogue receptor (GHSR / ghrelin receptor / GHS-R1a) expressed on pituitary somatotrophs and hypothalamic neurons, the growth hormone-releasing hormone receptor (GHRH-R) expressed on pituitary somatotrophs, and the insulin-like growth factor 1 receptor (IGF-1R) expressed broadly across peripheral tissues. The class is defined by mechanism of action on the somatotropic axis, per the pharmacological framework established by the Bowers laboratory at Tulane University with the original GHRP-6 characterization and extended through the identification of ghrelin as the endogenous GHSR ligand by the Kangawa laboratory.

Which Compounds Are Available in the True Peptide Labs Somatotropic Category?

The compounds available in the True Peptide Labs somatotropic research category, organized by receptor target and mechanism, are listed below. Each compound links to its dedicated product page with certificate of analysis, primary literature references, and lot-specific purity data.

• Ipamorelin (10 mg) — Pentapeptide GHSR agonist (Aib-His-D-2Nal-D-Phe-Lys-NH₂) characterized in the Novo Nordisk secretagogue program, selected for GH-selective release with minimal cortisol and prolactin activation relative to earlier GHRP compounds
• Ipamorelin + CJC-1295 No DAC (5 mg / 5 mg) — Peptide blend combining Ipamorelin with CJC-1295 No DAC, a modified GRF(1-29) GHRH analog developed in the ConjuChem program with tetrasubstitutions for enzymatic stability against DPP-IV cleavage; the "No DAC" designation indicates the short-half-life format without the Drug Affinity Complex albumin-binding modification
• Tesamorelin (10 mg) — GHRH analog based on GRF(1-44) with an N-terminal trans-3-hexenoyl modification for enzymatic stability, developed in the Theratechnologies program and characterized in the visceral adipose research literature; cross-listed from the metabolic category
• MK-677 Capsule — Ibutamoren, a non-peptide small-molecule GHSR agonist developed in the Merck secretagogue program, formulated as an oral capsule for orally bioavailable ghrelin-mimetic research
• IGF-1 LR3 (1 mg) — Long-Arg3 insulin-like growth factor 1 analog with N-terminal 13-amino acid extension and Arg substitution at position 3, engineered by the Adelaide research group for reduced IGFBP-3 binding and extended half-life relative to native IGF-1; cross-listed from the myogenic category

Each compound ships as lyophilized powder or oral capsule with a lot-specific certificate of analysis. Individual product pages provide the sequence, molecular weight, purity data, and primary literature citations for that specific compound.

What Is the Somatotropic Axis?

The somatotropic axis is the hypothalamic-pituitary-liver signaling system that regulates pulsatile growth hormone (GH) release and downstream IGF-1 production. The axis is organized as follows:

1. Hypothalamic level — GHRH neurons in the arcuate nucleus release GHRH into the hypophyseal portal circulation to stimulate pituitary GH release, and somatostatin neurons in the periventricular nucleus release somatostatin to inhibit GH release. The balance between GHRH and somatostatin tone determines the pulsatile pattern of GH secretion.
2. Ghrelin input — Ghrelin, released from stomach X/A-like cells and from hypothalamic neurons, acts at the GHSR on pituitary somatotrophs and on hypothalamic GHRH neurons to amplify GH release, providing a third regulatory input independent of the GHRH-somatostatin balance.
3. Pituitary level — Anterior pituitary somatotrophs express GHRH-R (Gs-coupled) and GHSR (Gq-coupled), and release GH in pulses in response to the integrated input from hypothalamic peptides.
4. Peripheral level — GH acts on hepatic and peripheral GH receptors (GHR) to stimulate production of IGF-1, which mediates many of the anabolic effects of GH and provides negative feedback to the hypothalamus and pituitary.
5. Feedback loops — IGF-1 provides long-loop negative feedback at the hypothalamus and pituitary; GH provides short-loop feedback at the hypothalamus. Somatostatin release is the major negative regulator of GH pulses.

What Are the Categories of Somatotropic Research Peptides?

The categories of somatotropic research peptides, organized by receptor target, are as follows:

1. Peptide growth hormone secretagogues (GHRP class) — including Ipamorelin, pentapeptide agonists at the GHSR selected for GH-selective release with minimal activation of the cortisol and prolactin axes that limited earlier GHRPs such as GHRP-6.
2. Non-peptide small-molecule GHSR agonists — including MK-677 (ibutamoren), orally bioavailable ghrelin mimetics developed from medicinal chemistry programs targeting oral administration and extended half-life.
3. Growth hormone-releasing hormone (GHRH) analogs — including CJC-1295 No DAC and Tesamorelin, modified GRF(1-29) and GRF(1-44) analogs engineered for enzymatic stability against dipeptidyl peptidase IV (DPP-IV) cleavage of the endogenous peptide's N-terminus.
4. GHRP + GHRH combination peptides — including the Ipamorelin + CJC-1295 No DAC blend, combining GHSR and GHRH-R activation to produce synergistic GH release in the same research vehicle.
5. Long-half-life GHRH analogs with albumin conjugation — the DAC-modified format of CJC-1295 (with the Drug Affinity Complex) that binds serum albumin covalently for extended half-life; the No DAC format available in this catalog represents the short-half-life alternative for pulsatile pharmacology research.
6. IGF-1 analogs — including IGF-1 LR3, the downstream effector of the somatotropic axis, engineered for reduced IGFBP-3 binding and extended plasma half-life for research on direct IGF-1R signaling.

Which Somatotropic Research Peptides Are Most Studied?

The somatotropic research peptides with the largest published footprint include the endogenous ligands GHRH, ghrelin, and IGF-1, each of which anchors an extensive receptor pharmacology literature. Among the synthetic research compounds, MK-677 and Ipamorelin anchor the GHSR agonist literature, characterized across multiple decades in the Merck and Novo Nordisk development programs and subsequent academic investigations. CJC-1295 anchors the modified-GRF GHRH analog literature from the ConjuChem program. Tesamorelin has been the subject of extensive clinical research given its FDA-approved status for HIV-associated visceral adipose research and represents the most translationally validated GHRH analog in current use. IGF-1 LR3 has served as the standard research analog for IGF-1R pharmacology for more than three decades since its characterization by the Adelaide research group. Individual product pages in this category link to the primary literature for each specific compound.

What Is the Importance of Somatotropic Research Peptides in Preclinical Science?

Somatotropic research peptides are important to preclinical science because they are the primary experimental tools for probing the pulsatile release, integrated regulation, and downstream signaling of the growth hormone axis in rodent and in vitro systems. The identification of ghrelin as the endogenous GHSR ligand by the Kangawa laboratory in 1999 established the third input to pituitary GH regulation and enabled a wave of GHSR-targeted pharmacology that continues today. Ipamorelin and MK-677 have served as reference compounds for GHSR-selective pharmacology and receptor characterization. CJC-1295 and Tesamorelin have enabled dissection of pulsatile versus tonic GHRH-R activation and its downstream consequences on GH pulse pharmacology. IGF-1 LR3 has served as the reference tool for dissecting direct IGF-1R signaling from combined GH-IGF-1 axis effects.

What Is the Difference Between GHRPs and GHRH Analogs?

Growth hormone-releasing peptides (GHRPs) and growth hormone-releasing hormone (GHRH) analogs are two distinct classes of somatotropic research compounds that engage different receptors and produce distinct GH pulse profiles:

1. Receptor target — GHRPs act at the growth hormone secretagogue receptor (GHSR / ghrelin receptor), while GHRH analogs act at the growth hormone-releasing hormone receptor (GHRH-R).
2. Endogenous ligand mimicry — GHRPs are synthetic mimetics of ghrelin, the endogenous GHSR agonist. GHRH analogs are modified versions of endogenous GHRH itself.
3. Downstream signaling — GHSR is Gq-coupled and activates phospholipase C, IP3, and intracellular calcium signaling. GHRH-R is Gs-coupled and activates adenylyl cyclase and cAMP. This differential coupling produces distinct GH release kinetics.
4. Somatostatin tone dependence — GHRH analog effects are strongly modulated by prevailing somatostatin tone (which competes at the somatotroph), while GHRP effects are less somatostatin-dependent.
5. Combination synergy — GHRPs and GHRH analogs produce synergistic (greater than additive) GH release when administered together, a hallmark pharmacological property that has driven the development of combination compounds such as the Ipamorelin + CJC-1295 blend.
6. Structural class — GHRPs include both peptide compounds (Ipamorelin, GHRP-6, hexarelin) and non-peptide small molecules (MK-677). GHRH analogs are all modified peptides based on the GRF(1-29) or GRF(1-44) sequence.

What Research Protocols Are Described in the Somatotropic Peptide Literature?

Published preclinical protocols for somatotropic peptides typically describe assay systems (radioligand binding at cloned GHSR or GHRH-R expressed in HEK293 cells, functional cAMP or IP3 assays, and pituitary somatotroph GH release assays), administration routes for in vivo work (subcutaneous and intravenous for peptides, oral gavage for MK-677 in rodent research), and endpoint measurements specific to each research question. Study designs include serial-sampling rodent models with jugular catheters for GH pulse characterization, somatostatin-blocked rodent models for maximal GH release characterization, aged rodent GH-decline models, and pituitary somatotroph primary culture assays for direct receptor pharmacology. Rodent studies commonly use blood sampling at 5–10 minute intervals to capture the pulsatile GH profile with sufficient time resolution. Researchers must consult peer-reviewed methodology sections and obtain approval from their institution's IACUC or IRB before designing any in vivo study, per NIH Office of Laboratory Animal Welfare guidance.

Are Somatotropic Research Peptides Studied in Combination?

Somatotropic research peptides are studied in combination in the published literature, and combination pharmacology represents one of the defining features of the field. GHRP + GHRH combinations produce synergistic (greater than additive) GH release because the two receptor classes engage independent mechanisms — GHSR activation amplifies pituitary somatotroph responsiveness while GHRH-R activation drives GH release itself. The Ipamorelin + CJC-1295 No DAC blend represents this combination in a single research vehicle. GHSR agonists have also been combined with somatostatin receptor ligands to dissect the balance between stimulatory and inhibitory inputs to somatotroph release. IGF-1 analogs have been studied in combination with GH secretagogues to characterize the relative contributions of pituitary-mediated versus direct IGF-1R signaling to downstream endpoints. All combination research described in the primary literature is conducted in laboratory settings under approved study protocols reviewed by the researcher's institution.

What Dose Ranges Appear in Published Somatotropic Peptide Studies?

Dose ranges in the published somatotropic peptide literature vary substantially by compound, model system, route of administration, and endpoint. Reported ranges span, for reference: microgram-per-kilogram subcutaneous for Ipamorelin in rodent GH-release characterization; microgram-per-kilogram subcutaneous for CJC-1295 No DAC in GHRH-R pharmacology studies; low-milligram-per-kilogram oral for MK-677 in rodent ghrelin-mimetic research; microgram-per-kilogram subcutaneous for Tesamorelin in rodent and non-human primate visceral adipose studies; and low-microgram to low-milligram per kilogram subcutaneous for IGF-1 LR3 in muscle protein synthesis research. Model systems include murine (C57BL/6J, aged cohorts for GH-decline studies), rat (Sprague-Dawley with jugular catheters for pulsatile GH sampling), non-human primate (for translationally relevant Tesamorelin work), and in vitro (HEK293 expressing GHSR or GHRH-R, dispersed anterior pituitary cell cultures). Specific compound product pages link to the primary literature where researchers can review the exact dose ranges reported for each study. This information is provided as literature reference only and does not constitute a recommendation for use.

What Endpoints Are Measured in Somatotropic Peptide Research?

The endpoints measured in somatotropic peptide research are as follows:

1. Serum growth hormone (GH) concentration — quantified by ELISA in serial serum samples following compound administration.
2. GH pulse amplitude and frequency — derived from time-series analysis of high-frequency serum sampling (typically 5–10 minute intervals) using dedicated pulse-detection algorithms such as Cluster or Deconv.
3. GH area under the curve (AUC) — integrated GH exposure over the sampling window as a measure of total secretory output.
4. Serum IGF-1 and IGFBP-3 — measured by ELISA to characterize the peripheral response to central GH release.
5. Cortisol and prolactin response — quantified as a selectivity index for GHRP-class compounds, with Ipamorelin distinguished from earlier GHRPs by minimal cortisol and prolactin release at GH-effective doses.
6. Receptor binding affinity (Ki) — quantified by radioligand competition at cloned GHSR or GHRH-R.
7. Functional cAMP accumulation (for GHRH-R) or IP3 / calcium mobilization (for GHSR) — measured in receptor-transfected cell lines.
8. Direct pituitary somatotroph GH release — assayed in dispersed anterior pituitary cell cultures.
9. Endogenous ghrelin displacement — assayed by radioligand competition against ghrelin at GHSR.
10. Sleep-associated GH pulse — quantified in rodent EEG/sampling protocols during slow-wave sleep periods.

How Is Receptor Selectivity Characterized in Somatotropic Peptide Research?

Receptor selectivity in somatotropic peptide research is characterized through parallel assays at the primary target (GHSR or GHRH-R) and at potentially off-target receptors within the pituitary hormone axis:

1. GHSR versus off-target selectivity — GHSR agonists are tested for cross-reactivity with the closely related motilin receptor and other GPCRs to establish specificity.
2. GH selectivity index — defined as the ratio of GH release potency to cortisol and prolactin release potency in vivo; this ratio distinguishes Ipamorelin from earlier GHRPs and is the primary selectivity claim for the compound.
3. GHRH-R versus VPAC1/VPAC2 selectivity — GHRH is structurally related to VIP and PACAP, and GHRH analogs are tested against VPAC receptors to establish selectivity.
4. Species comparison — the same compound is tested at mouse, rat, and human orthologs of GHSR and GHRH-R, as species differences in somatotropic pharmacology are documented.
5. Pulsatile versus tonic profile — the pharmacokinetic profile (short vs. extended half-life) determines whether a compound produces a pulsatile or tonic GH release pattern, with distinct downstream endocrine consequences.

What Signaling Pathways Do Somatotropic Research Peptides Engage?

The signaling pathways engaged by somatotropic research peptides in this category are as follows:

1. GHSR / Gq / phospholipase C / IP3 / calcium — the primary GHSR signaling pathway engaged by Ipamorelin and MK-677, leading to intracellular calcium mobilization in pituitary somatotrophs and hypothalamic GHRH neurons.
2. GHRH-R / Gs / adenylyl cyclase / cAMP / PKA — the primary GHRH-R signaling pathway engaged by CJC-1295 No DAC and Tesamorelin, leading to cAMP elevation and PKA-mediated GH release.
3. GH receptor (GHR) / JAK2 / STAT5 — the primary peripheral signaling cascade downstream of GH binding to the GHR, driving hepatic IGF-1 gene transcription and other GH-target-gene responses.
4. IGF-1R / PI3K / Akt / mTORC1 — the primary anabolic signaling pathway engaged directly by IGF-1 LR3 and indirectly through GH-driven IGF-1 production.
5. IGF-1R / MAPK / ERK1/2 — the proliferation-associated branch of IGF-1R signaling.
6. Somatostatin receptors (SST1–SST5) — the negative regulatory arm of the somatotropic axis, engaged endogenously and modulating the response to GH-releasing compounds.
7. Ghrelin receptor constitutive activity — GHSR displays substantial ligand-independent constitutive activity, characterized in the receptor pharmacology literature as a distinctive feature of this receptor.

What Model Systems Are Used in Somatotropic Peptide Research?

The model systems used in somatotropic peptide research are as follows:

1. Serial-sampling rat model with jugular catheter — the standard in vivo system for pulsatile GH characterization with 5–10 minute sampling intervals.
2. Aged rodent GH-decline models — C57BL/6J and other strains at 18–24+ months for characterizing compounds against age-associated somatopause.
3. Somatostatin-blocked rodent models — using somatostatin receptor antagonists or anti-somatostatin antibodies to reveal maximal GH release capacity.
4. Dispersed anterior pituitary cell cultures — from rat or mouse for direct somatotroph-level pharmacology.
5. HEK293 cells transfected with GHSR — the standard heterologous expression system for GHSR binding and functional assays.
6. HEK293 or CHO cells transfected with GHRH-R — for GHRH analog receptor characterization.
7. Non-human primate models — for translationally relevant somatotropic pharmacology, particularly for Tesamorelin research.
8. C2C12 murine myoblasts — for downstream IGF-1R signaling research relevant to muscle endpoints.
9. Ghrelin receptor knockout (Ghsr−/−) mice — for confirming GHSR-specificity of ghrelin mimetic effects.

What Adverse Events Have Been Reported in the Somatotropic Peptide Research Literature?

The adverse events reported in the published preclinical and clinical trial literature for somatotropic research peptides include injection-site observations (erythema, transient inflammation) for parenteral peptide compounds, dose-dependent effects on serum GH, IGF-1, cortisol, and prolactin documented in the trial safety data, and, for orally administered MK-677, effects on appetite and fluid retention documented in the clinical research record. Tesamorelin has an established human clinical trial safety profile from its FDA-approved indication for HIV-associated visceral adipose research, and the adverse event record is publicly available through FDA labeling documents. IGF-1 analogs have documented transient effects on serum glucose and insulin at higher doses. Some studies have found variable event rates that may be partly due to differences in dosing schedule, fed vs. fasted state, and titration across trials. Researchers must review the full published safety data for any specific compound before designing a study.

In What Form Do Somatotropic Research Peptides Ship?

Somatotropic research peptides from True Peptide Labs ship in the form appropriate to each product — lyophilized (freeze-dried) peptide powder in sealed sterile vials for injectable peptide compounds such as Ipamorelin, CJC-1295, Tesamorelin, and IGF-1 LR3; and oral capsules for MK-677. All products ship with a lot-specific certificate of analysis (COA) documenting purity by HPLC and mass by MS. Unopened peptide vials are typically stored refrigerated at 2–8°C per the storage instructions on the COA, and reconstituted material is stored per the published stability data for the specific compound. Cold-pack shipping options are available for temperature-sensitive compounds. All orders ship from the True Peptide Labs facility in Palm Beach Gardens, Florida.

How Are Somatotropic Research Peptides Tested for Purity?

Somatotropic research peptides at True Peptide Labs are tested every lot by third-party ISO-accredited analytical laboratories using high-performance liquid chromatography (HPLC) for purity determination and mass spectrometry (MS) for molecular weight confirmation. Certificates of analysis are lot-specific and are available on each product page or by request. Testing methodology follows the analytical standards described in the United States Pharmacopeia (USP) general chapter <1503> for peptide characterization.

How to Purchase Somatotropic Research Peptides Online

Somatotropic research peptides can be purchased directly through the True Peptide Labs catalog on this page. Products are sold exclusively for research use by qualified researchers, laboratories, and institutions, and are not available for human use. All orders ship from the Palm Beach Gardens, Florida facility with standard shipping and cold-pack options for temperature-sensitive compounds. By purchasing, buyers affirm the material will not be administered to humans or animals outside of an approved research protocol reviewed by their institution's IACUC or IRB.

What Is the Difference Between Somatotropic and Myogenic Research Peptides?

Somatotropic research peptides are defined by activity on the growth hormone axis — the hypothalamic-pituitary-liver signaling system that regulates pulsatile GH release and downstream IGF-1 production — while myogenic research peptides are defined by activity on skeletal muscle biology directly, including myoblasts, satellite cells, myofibers, and muscle-specific signaling pathways. The two categories overlap substantially because GH secretagogues and GHRH analogs produce their myogenic effects indirectly through pituitary GH release and hepatic IGF-1 production. The dedicated myogenic research peptides category page covers IGF-1 LR3 and the cross-listed somatotropic compounds under their primary skeletal-muscle-biology framework, and the metabolic research peptides category page covers Tesamorelin under its primary metabolic-endpoints framework.